April 17th 2024
Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.
April 11th 2024
The additional indication for benralizumab was supported by data from the phase 3 TATE trial.
March 7th 2024
The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.
February 29th 2024
Your daily dose of the clinical news you may have missed.
February 23rd 2024
New data presented at AAAAI 2024 sheds light on real-world patterns of biologic use in a diverse patient population with severe asthma.
Are Biologics for COPD Around the Corner? A Quick Look at the Literature
No biologic agent is approved to treat COPD, but progress is being made. Key developments of the past few years are summarized in this brief slideshow.
AAAAI 2021: Asthma Not an Independent Predictor of Severe COVID-19 Outcomes
Recent research presented at AAAAI 2021 Virtual Annual Meeting suggests asthma is not an independent risk factor for severe COVID-19 or hospitalization.
Significant Reductions in Exacerbations Seen in Broad Population of Severe Asthma Patients
Statistically significant reductions in annual exacerbation rates were seen across baseline eosinophil and exhaled FeNO level and allergy status with telepezumab, in the phase 3 NAVIGATOR trial.
Expert-guided Online Decision Tool Supports Real-time Treatment Choice for Severe Asthma
Treatment for severe asthma may be enhanced using an online decision support tool that draws on expert treatment decisions for a wide variety of potential patient scenarios.
Disease Severity of Asthma, COPD May Up Risk for Severe COVID-19
AAAAI Virtual Annual Meeting. Severity of underlying airways disease and not prior use of corticosteroids posed a risk of more severe COVID-19, a new study finds.
Asthma Patients with COVID-19 at Comparable Risk of Hospitalization
Patients with COVID-19 who have asthma share a similar risk of hospitalization with patients with the infection who do not have asthma, according to new research.
Use of Face Masks Does Not Affect Oxygen Saturation in Asthma Patients
AAAAI Virtual Annual Meeting. Among patients with asthma, wearing a mask, regardless of type or duration of use, had no significant effect on oxygen saturation.
AAAAI 2021 Virtual Annual Meeting: A First Look
Get a first look at key 8 studies to be presented at the upcoming AAAAI 2021 virtual meeting starting this Friday, February 26, 2021.
Biologic Eliminates or Reduces Oral Steroids in Severe Asthma: PONENTE Trial
AAAAI Virtual Annual Meeting. Two-thirds of severe asthma patients dependent upon oral corticosteroids stopped or maximally reduced use, according to the trial data.
High COVID-19-related Anxiety a Risk Factor for Worsening of Asthma, Quality of Life
In a new survey of patients with severe asthma, COVID-19-related anxiety was found to be a potential risk factor for clinical worsening of disease and decline in quality of life.
Half of Asthma Patients Who Use Cannabis Smoke or Vape, Survey Finds
A new survey of patients with asthma who use cannabis finds smoking and vaping preferred routes and that physicians rarely inquire about marijuana use.
NHLBI Updates Guidance for Asthma Diagnosis, Management, and Treatment
The NHLBI recently updated recommendations in 6 key areas of asthma diagnosis, management, and treatment, marking the first update of the guidance in over 10 years.
Asthma Research Update: 7 Studies At-a-Glance for Primary Care
Recent studies have reported the latest developments in asthma research. Scroll through these slides to find concise summaries of key points for clinical practice.
Guideline-directed Therapy for Asthma & COPD: Use This, Not That
Use ICS monotherapy for this, not that. For asthma COPD overlap, don't use that, use this. Try these 4 questions on GINA and GOLD recommended treatments.
Exacerbations in Asthma and COPD: A GINA & GOLD Guideline Quiz
Exacerbations of asthma and COPD have a negative impact on disease process in both conditions. Find out what you know about guideline-recommended mitigation.
Response to Dupilumab in Severe Asthma Predicted by Baseline FeNo
Increasing baseline FeNo levels were associated with reduced exacerbation and greater lung function improvement in dupilumab-vs-placebo-treated patients.
Increased Blood Eosinophil Counts, IgE Levels Linked to Higher Exacerbation Rates in Severe Asthma
Increased blood eosinophil counts and IgE levels are associated with higher exacerbation rates in patients with severe asthma, according to new research presented at ACAAI 2020.
Asthma, COPD, & Asthma-COPD Overlap: A Quiz in Differential Diagnostics
Distinguishing asthma and COPD can at times be problematic and the asthma-COPD overlap picture is even less clear. Check your recall of GINA/GOLD guidelines on all 3.
Severe Asthma: A 5-question POP Quiz
Severe asthma affects 5% to 10% of adults with asthma. Find out what you know about diagnosis and treatment options for these patients with 5 no-nonsense questions.
Tezepelumab for Severe Asthma Meets Phase 3 Primary Endpoint
The novel monoclonal antibody could bring relief to millions of persons with severe, uncontrolled asthma, including those with a low eosinophil phenotype.
ATS 2020: Masitinib Significantly Reduces Severe Asthma Exacerbations
New research presented at the American Thoracic Society virtual symposium showed the first-in-class drug reduced severe asthma exacerbation rate by 35% vs placebo.
CVD Mortality in COPD Related to Factors Other than Lung Function Decline
In COPD patients, a new study found no association between lung function decline and individual CVD outcomes, but disease exacerbations and dyspnea were implicated.
FDA Approves First Drug to Treat Group of Rare Blood Disorders in Over 10 Years
Mepolizumab (Nucala) received a new indication for the treatment of hypereosinophilic syndrome in patients aged ≥12 years.
Asthma: Long-acting Muscarinic Antagonists Overused, Up Exacerbation Risk
Long-acting muscarinic antagonists, recommended as add-on therapy for asthma, are too often used as monotherapy and are linked with severe exacerbations, a new study finds.
FDA Approves First Once-daily Single Inhaler Triple Therapy for Both Asthma, COPD Treatment
Along with COPD, fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) is now approved for the treatment of asthma in patients aged ≥18 years.
Adolescents Who Use E-cigarettes, Marijuana Have Higher Odds of Lifetime Asthma
New research presented at the ATS 2020 Virtual meeting shows adolescents who use e-cigarettes along with marijuana and/or cigarette smoking have significantly higher odds of lifetime asthma.
Discontinued Mepolizumab Treatment Increases Asthma Exacerbations
Continued mepolizumab treatment yielded clinical benefits in patients with severe eosinophilic asthma, suggests a new study being presented at the upcoming American Thoracic Society 2020 Virtual International Conference.
Asthma Linked with Incident CVD in Framingham Offspring Cohort Analysis
An independent association between asthma and risk of cardiovascular disease remained even after adjusting for other CVD risk factors, authors report.
Asthma, COPD Inhaler Adherence Up During Pandemic
Adherence to controller medication appears to have increased between early January and late March among patients with asthma and COPD, finds a new study.
Teens with Asthma Favor E-cigs, Hookah
Middle/high school students with asthma were found more likely to use 5 different tobacco products vs classmates without asthma.